Current challenges in interventional mitral valve treatment by Taramasso, Maurizio et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Current challenges in interventional mitral valve treatment
Taramasso, Maurizio; Candreva, Alessandro; Pozzoli, Alberto; Guidotti, Andrea; Gaemperli, Oliver;
Nietlispach, Fabian; Barthelmes, Jens; Emmert, Maximilian Y; Weber, Alberto; Benussi, Stefano;
Alfieri, Ottavio; Maisano, Francesco
Abstract: Transcatheter mitral valve therapies have emerged as an alternative option in high surgical
risk or inoperable patients with severe and symptomatic mitral regurgitation (MR). As multiple tech-
nologies and different approaches will become available in the field of mitral valve interventions, different
challenges are emerging, both patient- (clinical challenges) and procedure-related (technical challenges).
This review will briefly explore the current open challenges in the evolving fields of interventional mitral
valve treatment.
DOI: 10.3978/j.issn.2072-1439.2015.04.58
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-119873
Published Version
Originally published at:
Taramasso, Maurizio; Candreva, Alessandro; Pozzoli, Alberto; Guidotti, Andrea; Gaemperli, Oliver;
Nietlispach, Fabian; Barthelmes, Jens; Emmert, Maximilian Y; Weber, Alberto; Benussi, Stefano; Alfieri,
Ottavio; Maisano, Francesco (2015). Current challenges in interventional mitral valve treatment. Journal
of Thoracic Disease, 7(9):1536-1542. DOI: 10.3978/j.issn.2072-1439.2015.04.58
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2015;7(9):1536-1542www.jthoracdis.com
Introduction
Mitral regurgitation (MR) is the most prevalent valve 
disease in the western population and it is associated with 
reduced life expectancy and increased risk of heart failure (1).
Surgical intervention is indicated in presence of 
severe MR and symptoms of heart failure, or when 
patients present with reduced left ventricle (LV) function, 
pulmonary hypertension, or atrial fibrillation (2). However, 
up to 50% of the symptomatic patients with severe MR 
are not referred to surgery due to an expected high 
surgical risk (3). Transcatheter mitral valve therapies have 
emerged as an alternative option. Multiple technologies 
and diversified approaches are today under clinical study 
or in development. They can be categorized based on 
the anatomical and pathophysiological addressed target: 
leaflet and chordal repair procedures, indirect and direct 
annuloplasty, LV remodeling devices and valve replacement 
devices (4).
As multiple technologies and different approaches will 
become available in the field of mitral valve interventions, 
different challenges are emerging, both patient (clinical 
challenges) and procedure-related (technical challenges). 
This review will briefly explore the current open challenges 
in the evolving fields of interventional mitral valve treatment.
Clinical challenges
Increased complexity of the patients: the importance of a 
“global” patient selection
Clinical, ethical and economical implications
The increased complexity of the patients is strictly related 
to the increased expectancy of life and with the concept 
of “active ageing”. The prevalence of heart valve disease 
increases with age, with the predominance of degenerative 
etiology, as shown by the Euro Heart Survey on valvular 
heart disease (5). More than 10% of patients aged 75 years 
and more, requiring hospitalization, have significant MR (3). 
Many elderly patients are considered non-surgical candidates 
because of associated copathologies and high surgical risk.
In particular, in patients 80 years and older with severe 
MR, surgical treatment is performed in Europe only 
in 15%, as compared to 60% in patients aged 70 years 
and younger (3). With the availability of less invasive 
interventional mitral therapies, the clinical issue of the 
evaluation of the balance between utility vs. futility of any 
invasive treatment for each patient is raising, given the 
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possibility of no improvement in the quality of life and 
no gaining independence back, even if the intervention is 
successful and the patient survives. Assessing the delicate 
point in which the clinical benefit is overpassed by the 
poor value or futility of the procedure is the biggest clinical 
challenge of physicians in this context. Multidisciplinary 
evaluation is mandatory to define the most appropriate 
therapy for each patient, taking into account the clinical 
status, the expected surgical risk and the anatomy of the 
mitral lesion (6).
Moreover, ethical implications should be taken 
into account. The therapeutic decision in this context 
should be reached also by informing the patient and the 
family thoroughly, taking into account their perspective. 
Concomitantly, the economic burden in high-risk elderly 
patients has crucial implications and should be considered 
before proceeding, due to reduced expectancy of life.
From a palliative to a prognostic approach?
Improved safety and efficacy, need for experienced 
operators specifically trained, combined approach in 
selected cases
The clinical target of interventional mitral valve treatment 
will probably move in the next future from a palliative 
towards a prognostic approach. Clinical experience with 
mitral valve intervention (both surgical and transcatheter) 
clearly demonstrated that early timing is crucial to 
accomplish substantial prognostic benefit (7-9): early repair 
can restore expectancy of life in degenerative MR (DMR) 
patients and induce reverse remodelling in functional 
MR (FMR). On the contrary, in patients treated in a 
too advanced phase of the disease, transcatheter mitral 
procedures may be unable to influence the prognosis (10,11). 
The safety of the procedure is fundamental to justify any 
early indications and probably plays a predominant role over 
efficacy in this specific context. Proven that transcatheter 
mitral valve therapies are relatively safe even in high-risk 
patients (12,13), the question of “how less efficacious is 
efficacious enough” patients is crucial to expand indications 
in lower risk patients. 
The definition of a specific and shared educational 
training program of an interventional mitral valve 
operator (including both surgical and interventional skills) 
will represent a major challenge for the cardiovascular 
community in the next years.
Reproducibility of the procedures and experience 
of the operators play a fundamental role. In particular, 
every operator should become confident with different 
transcatheter devices in order to select the most appropriate 
approach for each patient and for different mitral 
anatomies. In selected cases, also a combination of different 
device should be taken in consideration in order to tailor 
the approach and to optimize the outcomes (i.e., leaflet 
repair and transcatheter annuloplasty in the same patient).
Technical challenges 
New technologies and new approaches
Efficacy, reproducibility, versatility and technical complexity
Different anatomical lesions and aetiologies may underlie 
MR. Therefore, a series of different technologies and 
devices should be available. They can be categorized 
based on the anatomical and pathophysiological addressed 
target: leaflet and chordal repair procedures, indirect and 
direct annuloplasty and LV remodeling devices. Operators 
dedicated to transcatheter mitral interventions should 
become expert in using more than one device, in order 
to improve the outcomes and to increase the number of 
the patients potentially eligible for interventional mitral 
treatment.
Currently, MitraClip (Abbott Vascular, USA) has been 
a winning device mainly because it is versatile, and it can 
be used both in patients with FMR and DMR. Clinical and 
anatomical efficacy have been reported even in high-risk or 
inoperable patients with both functional and degenerative 
aetiologies (about 80% of the patients in NYHA class 
I-II 1 year after the procedure; about 80% of the patients 
with MR ≤2+ at 1 year) (12,14). MitraClip is CE Marked 
since 2008 and it also obtained FDA approval in 2013 for 
symptomatic patients with severe DMR at too high risk for 
surgery. About 20,000 patients have been worldwide treated 
up today.
However, MitraClip implantation is a procedure very 
different from other interventions.
Beyond the transseptal puncture, the procedure is more 
a robotic “surgical like” endovascular procedure, with 
free-floating navigation in a three-dimension (3D) space. 
Advanced 3D echocardiographic guidance is fundamental to 
obtain good results. 
From a technical standpoint, most repair technologies on 
the horizon require advanced and specific skills.
Some technologies for transcatheter mitral repair are 
easier to perform, such as coronary sinus annuloplasty 
(indirect annuloplasty), which is based on the anatomical 
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proximity of the coronary sinus to the posterior mitral 
annulus. This approach is particularly attractive because 
the cannulation of the coronary sinus is an easy and 
reproducible venous access technique. Initial results with 
this approach have not been satisfactory, mainly due to 
suboptimal efficacy and the risk of delayed complications 
(including coronary occlusion). 
The Cari l lon Mitral  Contour System (Cardiac 
Dimension, Inc., Kirkland, Washington) is the only 
technology still using this approach. It has recently 
obtained CE mark. The TITAN trial, which evaluated the 
clinical impact of Carillon Mitral in HF patients with at 
least moderate FMR, demonstrated significant reductions 
in FMR and in LV volumes. Functional status (including 
walking test performance) markedly improved in the 
implanted patients (15).
Although clinical benefits have been observed, this 
approach has a restricted applicability in the real world, 
mainly due to its limited efficacy (due to the fact that 
coronary sinus and mitral annulus are not coplanar) and 
to the risk of coronary artery compression and device 
dislocation. 
Recently direct annuloplasty is becoming available. 
Direct mitral valve annuloplasty repair is a very promising 
approach for transcatheter mitral valve repair, since it 
closely reproduces a gold-standard surgical method. The 
Cardioband (ValtechCardio Inc, Israel) is the closest 
transcatheter device to a surgical prosthetic ring. Delivered 
through a transseptal access, the implant of a surgical-like 
adjustable Dacron band is performed on the atrial side of 
the mitral annulus, from trigone to trigone, by means of 
multiple anchors (16,17). Ongoing CE trial is enrolling 
high-risk patients with FMR and initial clinical data are 
promising, showing significant reduction of MR and 
improved functional status after the procedure. 
Promising initial clinical results have been showed 
also with the Mitralign device (Mitralign, Inc, USA), 
which performs selective plication of the mitral annulus 
by deploying couples of trans-annular pledgets in the 
annulus (18). Patient enrollment in the CE mark trial is 
completed, but the device is still not available for clinical use. 
The Accucinch System (Guided Delivery Systems, 
USA) is another direct annuloplasty device that uses the 
retrograde transventricular approach. The Accucinch 
System also causes remodeling of the basal portion of the 
LV, promoting papillary muscle approximation, and is 
unique in this respect. Limited clinical data are available.
Today, the main concern about mitral direct annuloplasty 
repair is that these procedures are technically very 
challenging and require advanced integrated imaging 
guidance (Figure 1): these aspects could limit their rapid and 
effective adoption in the real world.
Beyond indirect and direct annuloplasty, other methods 
have been attempted to remodel the mitral annulus, 
including external compression of atrio-ventricular 
groove, implant of cinching devices and application of 
radiofrequency or ultrasound energy sources to shrink 
the annular collagen (19-22). Reproducibility, efficacy 
and safety of these appealing technologies needs still 
to be proved because they are based on novel concepts, 
without a validated and reproducible surgical or preclinical 
background.
The transcatheter repair armamentarium includes also 
artificial chordae implantation, which are anchored to the 
LV apex to restore mitral valve competency (NeoChord, 
Inc., Eden Prairie, Minnesota) (23). This procedure is 
performed through a transapical, off-pump, beating heart 
approach. It has been used successfully in several patients, 
with the evidence of a learning curve. Long-term durability 
of this approach remains an issue. 
Different ventricular or atrial remodelling devices 
complete the wide spectrum of repair technologies, but 
limited clinical data are today available for these approaches. 
Figure 1 Multimodal i ty  imaging procedural  guidance 
(bidimensional Echo, 3D Echo and fluoroscopy) during direct 
mitral annuloplasty.
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Transcatheter mitral valve replacement is an emerging 
clinical field. Percutaneous mitral valve replacement has 
proved to be feasible as valve-in-valve and valve-in-ring 
procedure in patients at high surgical risk (24). Moreover, 
the feasibility of the implant of a percutaneous balloon-
expandable aortic prosthesis in a native severely calcified 
mitral valve has been reported (25). The feasibility of 
transcatheter mitral valve implantation in native non-
calcified valves has been recently reported in very high-risk 
patients, mainly with FMR (26).
When mitral replacement technologies will become 
clinically available, it will be even more difficult to identify 
the ideal therapy for the individual patient. The valves 
that have been today implanted in native mitral position 
are self-expandable prosthesis, mainly delivered through 
the transapical route (less than 20 cases overall have been 
reported with different devices). Mitral replacement may 
offer some theoretical advantages, as reproducibility 
and applicability to majority of patients, with a high 
predictable and less technically demanding procedure. 
However, transcatheter mitral valve repair, although more 
complex and technically challenging, is more physiological 
and therefore associated with a superior safety profile, 
as compared to replacement, since it does not involve 
a heterologous tissue implant and does not require 
anticoagulation. The overall balance between advantages 
and disadvantages of the two approaches introduces the 
need for patient-specific tailored approach. In the future, 
transcatheter mitral repair and replacement will probably 
have a complementary role rather than competitive. Specific 
algorithms with specific indications will be required to 
guide the optimal treatment for each patient.
Integrated imaging 
Pre-procedural screening, patient selection and intra-
procedural guidance
Given the previously mentioned complex pathophysiology of 
mitral valve disease, the need of a full-comprehensive assessment 
of the valvular anatomy, the adjacent cardiac and extra-cardiac 
structures and the peripheral accesses must be performed in the 
pre-operative evaluation. Hence, a multi-disciplinary formation 
with a vast understanding in both sonographic and tomographic 
images is already become a fundamental skill of the modern 
interventional mitral valve operator. 
With minor differences that may be detected if 
looking at the single centre case, all patients referred 
for percutaneous operation on mitral valve are routinely 
enrolled in preoperative protocols, which generally 
include a chest X-ray, a coronarography, a combined trans-
thoracic echocardiography (TTE) and trans-esophageal 
echocardiography (TEE). In fact, a preoperative extensive 
study of the mechanism of regurgitation and the valvular 
anatomy, inclusive of details on the localization of the 
regurgitant orifice, the presence of anatomical features that 
are associated to poor implant success (e.g., short grasping 
area, presence of clefts) or higher operative risk (e.g., 
extensive calcification of the annuls), is mandatory for the 
decision making. The integration of 3D reconstructions 
on TEE has been tested and reported as a powerful tool 
on preoperative screening for MR (27). Nevertheless, 
sub-optimal sonographic windows, heavy calcification or 
contraindication to TEE may impair this fundamental 
diagnostic step. 
In order to avoid these complications and to simplify 
the reading of the images by the operators, advances in 
imaging techniques such as multidetector row computed 
tomography (MDCT), and cardiac magnetic resonance 
(CMR) may be helpful especially when integrated in a 
multimodality approach (28).
Multiphase retrospectively gated MDCT with its 
high degree of image quality and short acquisition 
time is typically required for assessment of valvular 
structure (29) good grade of correlation with TTE and 
CMR (30). Geometrical analyses of valvular and sub-
valvular apparatus (e.g., annulus deformation, papillary 
muscles displacement and changing in leaflets angles) and 
of the relationship between mitral valve and other adjacent 
structures (e.g., coronary-sinus dimension, aorto-mitral 
angle, aorto-trigonal distance and distance from left atrial 
appendage) may also be accomplished by MDCT (31). 
This is the reason why, in preclinical context, MDCT is the 
method of choice in the preoperative screening for direct 
annuloplasty devices and this statement is also extendible in 
clinical practice (32). Interestingly, MDCT can be used to 
optimize operative fluoroscopic viewing angles of left-sided 
heart structures (33). Other advantages of these imaging 
modalities on the sonographic techniques are the output 
of useful 3D datasets with high-resolution submillimeter 
isotropic voxels, the concomitant evaluation of the coronary 
arteries and other cardiac and extracardiac structures of 
interest. 
Less clear is the role of preoperative CMR in patients 
who are undergoing a percutaneous MV intervention. 
With regards to patients treated with MitraClip, CMR has 
been proven to be a useful tool in both preoperative and 
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follow-up phase providing clinicians with a quantitative 
assessment of MR severity, insights into the mechanism of 
regurgitation, and an assessment of the consequences of the 
regurgitant lesion on LV volumes and systolic function (34).
Once again, MDCT can be used in patient populations 
that are unable to undergo CMR studies, such as patients 
with claustrophobia, pacemakers, and implantable 
defibrillators. 
Intraprocedural  imaging for percutaneous MV 
interventions represents the actual real challenge for 
imaging. The complexity of manoeuvring through TEE 
and fluoroscopy guidance steerable catheters delivering 
clips, artificial valves or anchors in the narrow 3D space 
of the left heart chambers could be often addressed as the 
reason for a suboptimal implantation, long operative and 
fluoroscopic time and intraoperative complications. Given 
the importance for the navigation of the device on the 
beating heart and the expected optimal control on MR, 
the huge amount of hybrid imaging systems, consisting of 
fluoroscopy and echocardiography, are increasingly selected 
for intraoperative support. 
Intracardiac echocardiography (ICE) is an emerging 
modality commonly used only in preclinical phase. Even 
though the attractive promise of removing sedation or 
general anaesthesia associated with TEE, this technique 
allows the inspection from only one projection, with 
different degree of freedom. 
As mentioned above, specific preoperative MDCT 
analyses may be used to simplify the deployment of the 
valve prosthesis by pre-selecting optimal fluoroscopic 
viewing angles (33).
A new hybrid imaging system, consisting of an overlay 
3D-MDCT data onto the real-time procedural fluoroscopy 
(HeartNavigator software, Philips Healthcare, Best, 
Netherlands), was also found to be feasible and to provide 
a simplified procedural guidance for complex structural 
cardiac intervention (Figures 2,3).
Conclusions
As multiple technologies and different approaches will 
become available in the field of mitral valve interventions, 
different clinical and technical challenges are emerging, 
facing with the rapid increase of the number of potential 
patients who are not amenable for conventional surgery. 
New and reproducible procedures, advanced integrated 
imaging modalities, specific hybrid training programs and 
a modern heart-team approach are the keys to overcome all 
the challenges of interventional mitral valve treatments.
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